Pulse Biosciences (NASDAQ:PLSE) Shares Up 7.3%

Shares of Pulse Biosciences, Inc. (NASDAQ:PLSE) shot up 7.3% during mid-day trading on Thursday . The stock traded as high as $10.74 and last traded at $10.70. 32,514 shares traded hands during trading, a decline of 84% from the average session volume of 199,633 shares. The stock had previously closed at $9.97.

Analyst Ratings Changes

Separately, StockNews.com raised Pulse Biosciences to a “sell” rating in a research report on Thursday.

Pulse Biosciences Stock Performance

The company has a 50-day moving average of $10.06 and a 200-day moving average of $9.55.

Pulse Biosciences (NASDAQ:PLSE) last issued its earnings results on Tuesday, May 7th. The company reported ($0.17) earnings per share for the quarter.

Insiders Place Their Bets

In related news, CEO Burke Thomas Barrett acquired 10,000 shares of the business’s stock in a transaction that occurred on Monday, May 20th. The shares were acquired at an average cost of $8.56 per share, for a total transaction of $85,600.00. Following the completion of the purchase, the chief executive officer now directly owns 10,000 shares in the company, valued at $85,600. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. 71.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Pulse Biosciences

Hedge funds and other institutional investors have recently modified their holdings of the stock. PNC Financial Services Group Inc. bought a new stake in shares of Pulse Biosciences during the fourth quarter valued at about $242,000. Cetera Advisors LLC acquired a new position in Pulse Biosciences during the first quarter worth about $109,000. Price T Rowe Associates Inc. MD acquired a new position in Pulse Biosciences during the first quarter worth about $88,000. Vanguard Group Inc. grew its holdings in Pulse Biosciences by 28.8% during the first quarter. Vanguard Group Inc. now owns 847,212 shares of the company’s stock worth $7,379,000 after acquiring an additional 189,227 shares during the period. Finally, BNP Paribas Financial Markets grew its holdings in Pulse Biosciences by 63.6% during the first quarter. BNP Paribas Financial Markets now owns 7,597 shares of the company’s stock worth $66,000 after acquiring an additional 2,952 shares during the period. 76.95% of the stock is currently owned by institutional investors.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.